Latest Breaking News On - சந்தைப்படுத்தல் அங்கீகாரம் - Page 9 : comparemela.com

Bristol Myers Squibb Receives European Commission Approval for Onureg (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia

Bristol Myers Squibb Receives European Commission Approval for Onureg (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South australiaUnited statesUnited kingdomAndrew weiNina goworekNoah berkowitzBristol myers squibbMonash universityHematology developmentEuropean commissionBristol myers squibb companyExchange commissionEuropean unionAmerican cancer societyMyers squibbMarketing authorization

Bristol Myers Squibb Receives European Commission Approval for Onureg® as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia

Bristol Myers Squibb Receives European Commission Approval for Onureg® as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

FDA Says It Won t Approve Orphazyme s NPC Therapy without Additional Data

FDA Says It Won t Approve Orphazyme s NPC Therapy without Additional Data
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United statesChristophe bourdonDrug administrationSeverity scaleNew drugMarketing authorizationஒன்றுபட்டது மாநிலங்களில்கிறிஸ்டோஃப் பெர்டோன்தீவிரம் அளவுபுதியது மருந்துசந்தைப்படுத்தல் அங்கீகாரம்

Emmaus Life Sciences Announces Submission of Marketing Authorization Application to Swissmedic Ideogen, A G to Manage Early Access Program

Emmaus Life Sciences Announces Submission of Marketing Authorization Application to Swissmedic Ideogen, A G to Manage Early Access Program
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesYutaka niiharaMurat gokerGeorge sekulichExchange commissionPrnewswire emmaus life sciences incEmmaus life sciencesIsraeli ministry of healthEmmaus life sciences incUniversity of zurichSwiss agency for therapeutic products swissmedicLife sciencesSwiss agencyTherapeutic productsMarketing authorizationIsraeli ministry

Catalyst Pharmaceuticals, Inc s and KYE Pharmaceuticals

Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi® June 03, 2021 13:20 ET | Source: Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc. - Without an NOC, Ruzurgi is without a Marketing Authorization in Canada - Matter Remanded Back to Health Canada to Provide a More Transparent Record of Its Decision in Light of Firdapse ® ’s Data Protection CORAL GABLES, Fla., June 03, 2021 (GLOBE NEWSWIRE) Catalyst Pharmaceuticals, Inc. ( Catalyst ) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, and KYE Pharmaceuticals Inc. ( KYE ), a private company headquartered in Mississauga, Ontario and focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, to

United statesDouglas reynoldsPatrickj mcenanyHealth canada onCatalyst pharmaceuticalsCanadian federal courtUs food drug administrationCatalyst pharmaceuticals incPharmaceuticals incHealth canadaMarketing authorizationRemanded backMore transparent recordIts decisionNew drug submissionJacobus pharmaceutical